Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

Asgard Therapeutics United Kingdom United States of America Sweden

Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalitiesAT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responsesView original content:https://www.prnewswire.co.uk/news-releases/asgard-therapeutics-appoints-immunology-expert-shane-olwill-as-chief-development-officer-302411069.html